在真实临床实践中接受司库奇尤单抗治疗24个月的中轴型脊柱关节炎和银屑病关节炎患者的患者报告结局
该研究纳入16个欧洲注册中心的3087例中轴型脊柱关节炎(axSpA)和3246例银屑病关节炎(PsA)患者,评估司库奇尤单抗治疗6、12、24个月的患者报告结局(PRO)缓解率及24个月留存率。粗PRO缓解率axSpA高于PsA,但经药物依从性校正(LUNDEX)后两组相似;多因素校正后两组PRO缓解无差异,24个月留存率也相似(HR 0.92,95%CI 0.84-1.02)。
要点
- 粗疼痛、疲劳、PGA和HAQ缓解率axSpA高于PsA,LUNDEX校正后两组相似。
- 多因素校正后,axSpA与PsA的PRO缓解率无差异。
- 24个月留存率axSpA vs PsA的HR为0.92(95%CI 0.84-1.02)。
核心结论
- 在这项大型欧洲真实世界研究中,经混杂因素校正后,axSpA与PsA患者接受司库奇尤单抗的PRO缓解率和治疗留存率相当。
研究设计与样本
- 来自16个欧洲注册中心、在常规诊疗中启动司库奇尤单抗的axSpA或PsA患者。
- 共纳入3087例axSpA和3246例PsA患者。
- PRO缓解定义为疼痛、疲劳、PGA≤2(NRS 0-10)和HAQ≤0.5,计算粗值和LUNDEX校正值。
- 采用逻辑回归比较axSpA与PsA的缓解率(未校正和校正多个混杂因素)。
- 采用Kaplan-Meier图、log-rank检验和Cox回归评估和比较司库奇尤单抗留存率。
主要发现
- 粗疼痛、疲劳、PGA和HAQ缓解率axSpA高于PsA,而LUNDEX校正后缓解率相似。
- 校正混杂因素后,两组患者间无差异。
- 完全校正分析中,24个月留存率axSpA vs PsA的HR为0.92(95%CI 0.84-1.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. PATIENTS AND METHODS: Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0-10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed using logistic regression analyses (unadjusted and adjusted for multiple confounders). Kaplan-Meier plots with log-rank test and Cox regression analyses were conducted to assess and compare secukinumab retention rates. RESULTS: We included 3087 axSpA and 3246 PsA patients initiating secukinumab. Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar. No differences were found between the patient groups after adjustment for confounders. The 24-month retention rates were similar in axSpA vs. PsA in fully adjusted analyses (HR [95 %CI] = 0.92 [0.84-1.02]). CONCLUSION: In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.
引用
- Christiansen SN, Horskjær Rasmussen S, Pons M, et al. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice. Semin Arthritis Rheum. 2024. PMID: 38301349. doi:10.1016/j.semarthrit.2024.152388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。